Compare VanEck Gold Miners ETF (GDX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Sanofi SA — how do they compare? VanEck Gold Miners ETF trades at $89.28 (market cap $25.65B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.7× VanEck Gold Miners ETF's market cap, and Sanofi SA pays a 6.01% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Sanofi SA for 94 Days on average.
| GDX | SNY | |
|---|---|---|
Market Cap | $25.65B | $95.18B |
Volume | 16,534,046 | 2,995,646 |
52-Week High | $115.84 | $52.34 |
52-Week Low | $68.28 | $39.51 |
Typical Hold Time | 76 Days | 94 Days |
Sector | — | Health |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX (VanEck Gold Miners ETF) trades at $86.74, up 1.5% on the day but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased stakes significantly.
The outlook remains cautious with technical indicators pointing bearish, though gold's resilience amid rising rates provides fundamental support. Key risks include interest rate sensitivity and metals price volatility, while the valuation gap between physical gold and miners presents a potential opportunity if gold maintains strength.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
